SMA-and MAD-related protein 7 (SMAD7) is a general inhibitor of transforming growth factor-β (TGF-β) signaling that acts through interaction and degradation of TGF-β receptors. SMAD7 has been demonstrated to be transcriptionally upregulated in chemical-induced skin tumors and TGF-β-treated normal keratinocytes. To evaluate the function of SMAD7 in skin carcinogenesis in vivo, Smad7 transgenic mice that specifically express either wild-type (WT) SMAD7 (TG-Smad7-WT) or mutant SMAD7 (TG-Smad7-MT) in keratinocytes, as well as Smad7 keratinocyte-specific knockout (Smad7 2f/2f -K14Cre) mice, were subjected to chemical-induced skin carcinogenesis. WT-SMAD7-expressing transgenic mice showed significantly greater papilloma formation than did non-TG control and Smad7-MT mice. The expression of WT-SMAD7 attenuated DNA damage-induced apoptosis in epidermal keratinocytes by stimulating the ATM-dependent DNA repair pathway. Nonetheless, overexpression of WT-SMAD7 caused a susceptibility to 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperproliferation through activation of epidermal growth factor (EGF) signaling. In agreement with the transgenic mouse data, keratinocyte-specific deletion of SMAD7 markedly suppressed the tumor formation by inhibiting ATM and epidermal growth factor receptor (EGFR) signaling. Moreover, specific inhibition of EGFR signaling attenuated the hyperproliferation and tumor formation in TG-Smad7-WT mice. Taken together, these data support a novel role for SMAD7 as a tumor promoter in skin carcinogenesis where SMAD7 stimulates the DNA repair pathway and EGFR signaling activation.
Introduction
SMA-and MAD-related protein 7 (SMAD7) has been identified as an inhibitor of transforming growth factor-β (TGF-β) signaling that interacts with TGF-β receptor and prevents TGF-β1-induced signaling (1) . Expression of SMAD7 is modulated by various stimuli including TGF-β, interferon-γ, tumor necrosis factor-α as well as ultraviolet light and 12-O-tetradecanoylphorbol-13-acetate (TPA) and regulates the cross talk between TGF-β and other signaling pathways (2, 3) . Increasing evidence indicates that deregulation of SMAD7 expression is associated with human cancers by either promoting or suppressing cancer cell growth. Genetic polymorphism of Smad7 is related to colorectal cancer and sustained cell growth and survival through suppression of apoptosis (4, 5) . Another report has also revealed the increased mRNA expression of Smad7 in both human pancreatic tissues and pancreatic cancer cell lines (6) . High expression of SMAD7 correlates with a low survival rate among gastric cancer patients and aggressive metastatic phenotypes (7) . SMAD7 overexpression in H-ras-transduced keratinocytes also promotes the formation of malignant cells and progression to squamous cell carcinoma by inhibiting the TGF-β signaling and upregulating the epidermal growth factor (EGF)-like superfamily (8) . Nonetheless, the detailed mechanism behind SMAD7-driven modulation of cell growth and carcinogenesis has not yet been elucidated in an in vivo model. EGF signaling regulates fundamental functions coordinating tissue development and homeostasis (9) . In the skin, epidermal growth factor receptor (EGFR) ligands are actively synthesized by keratinocytes and EGFR activation regulates essential processes of skin development, wound healing and carcinogenesis (10) . Given that ErbB signaling is important for the proliferation of epithelial cells, it is also modulated during the progression of skin cancer. Multiple EGFR ligands (amphiregulin, HB-EGF and TGF-α) are coordinately upregulated during skin cancer promotion, leading to EGFR activation (11) . Some studies suggest that EGFR signaling is significantly activated in mouse tissue after treatment with several skin cancer-promoting agents including TPA, okadaic acid and chrysarobin (12) . Moreover, EGFR is highly overexpressed and constitutively activated in skin tumors including papillomas and squamous cell carcinomas. Transgenic mice overexpressing either TGF-α or EGFR have epidermal hyperplasia and are highly sensitive to two-stage skin carcinogenesis. Accordingly, inhibitors of EGFR-MEK signaling suppress TPA-mediated activation of inflammatory genes and a dominant-negative EGFR mutation suppresses the formation of skin cancer in a transgenic mouse model (13) .
The two-stage model of mouse skin carcinogenesis represents one of the best established in vivo models for studying the sequential and stepwise progression of skin tumors (14) . In this model, a single topical treatment with an initiator, 7,12-dimethylbenz(a)anthracene (DMBA), is followed by repetitive application of a tumor promoter, TPA, to induce the skin tumors. During the initiation stage, DMBA induces an irreversible and specific mutation of oncogene H-ras in mouse skin (15) . The population of mutated cells is expanded and believed to have a growth advantage over neighboring cells; this advantage allows for selective expansion to the promotion stage (16) . The end point of tumor promotion is the development of papillomas, some of which will regress whereas others can convert into squamous cell carcinomas.
Here, we demonstrated a pro-tumorigenic role of SMAD7 using in vivo models (transgenic and knockout mice) for analysis of two-stage carcinogenesis. We found that SMAD7 promotes papilloma formation by acting at both the initiation stage and promotion stage of skin carcinogenesis. In the early stage of carcinogenesis, SMAD7 suppressed the DNA damage-induced apoptosis to maintain the pre-transformed state of cells. In the promotion stage, SMAD7 activated cell proliferation through stabilization of EGFR. Furthermore, we observed constitutive activation of EGFR signaling in both TPA-treated skin and in papillomas. Mechanistically, overexpression of SMAD7 prevented the DNA damage-induced cell death and elevated EGFR activity, thereby promoting skin carcinogenesis.
Materials and methods

Reagents
Antibodies against SMAD7 (sc-7004), EGFR (sc-03) and p-EGFR (sc-81487) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Antibodies against p-ATM (5883), p-H2AX (9718S), p-ERK (4377S), cyclin D (2922) and p-STAT3 (9145) were acquired from Cell Signaling Technology (Beverly, MA), whereas the antibody against NBS1 (ab23996) was purchased from Abcam (Eugene, CA). The anti-PCNA antibody (13-3900) was bought from Thermo Fisher (Waltham, MA), whereas anti-β-actin (A5441) and anti-FLAG (M2, F1804) antibodies and DMBA from Sigma-Aldrich (St. Louis, MO). TPA was purchased from LC Laboratories (Woburn, MA).
Generation of Smad7 mouse strains
The wild-type (WT) Smad7 transgenic mice were generated as previously reported and backcrossed into the C57BL/6 strain (17) . A mutant Smad7 construct that contains point mutations at TAB2-and TAB3-binding sites ( 349 NPDSRT 354 / 349 APGARA 354 ) was inserted into the K5 vector via the same strategy as in another study (Supplementary Figure 1A , available at Carcinogenesis Online) (2, 17) . The transgenic mice were genotyped by PCR analysis of tail DNA with specific primers Supplementary Table 1 , available at Carcinogenesis Online). To generate the Smad7-conditional knockout mouse strain, a recombineering system was used to construct a conditional knockout vector for targeting Smad7. A 10.6 kb genomic DNA fragment including exons 1 and 2 of Smad7 was cloned into the pLMJ235 plasmid. The loxP sequence and frt-loxP-Neo-frt-loxP cassette, containing a positive selection marker (Neomycin resistance gene), were inserted 506 bp upstream and 327 bp downstream of exon 1, respectively. The linearized targeting vector was electroporated into J1 embryonic stem cells. Five correctly targeted clones were selected by Southern blot analyses with external 5′-and 3′-probes. The engineered embryonic stem cells were injected into C57BL/6 blastocysts. Male chimeras were crossed with C57BL/6 females and germline transmission of the targeted allele (Smad7 3f ) was confirmed by Southern blotting. To remove the Neo cassette from the Smad7 3f allele, Smad7 +/3f mice were crossed with Flpdeleter mice. To generate the mice with a keratinocyte-specific Smad7 knockout, Smad7 2f/2f -homozygotes were crossed with transgenic mice expressing Cre recombinase under control of the keratin 14 promoter (Supplementary Figure 1B, 
The protocol of two-stage skin carcinogenesis
The C57BL/6 transgenic and knockout mice were subjected to the described experiments at 6-8 weeks of age. The skin of a mouse was shaved 48 h before treatment with DMBA. For the two-stage carcinogenesis experiment, mice were treated with single topical application of DMBA (25 µg in 200 µl phosphate-buffered saline). One week after initiation, TPA (5 µg/200 µl) was applied topically twice weekly for 20 weeks. The mice were euthanized and skin tumors were collected after 25 weeks. Skin tissues and tumors were excised and either frozen or fixed in formalin for further analysis. All the animal experiments were performed in accordance with the guidelines approved by the institutional animal care and use committee of Gachon University, Incheon, Korea.
Immunohistochemical analysis
Formalin-fixed, paraffin-embedded tissues were deparaffinized and hydrated by standard procedures and cut into thin slices. Slide-mounted tissue sections were incubated with 0.03% hydrogen peroxide for 10 min and microwaved for 10 min with 10 mM citrate buffer (pH 6.0) containing 0.01% Tween 20. The slides were then incubated overnight at 4°C with the anti-PCNA antibody was diluted in 1% bovine serum albumin in phosphate-buffered saline. After 24 h, the slides were incubated for 40 min with a secondary antibody and processed by a mounting medium. The stained proteins in the sections were visualized with diaminobenzidine (Dako, Carpinteria, CA) and quantitative analysis of the stained cells was performed in the MetaMorph software (Universal Imaging Corp, Burnaby, British Columbia, Canada).
A TUNEL assay
This assay was performed to measure nuclear DNA fragmentation in apoptotic cells using a DeadEnd Fluorometric TUNEL System (Promega, Madison, WI). Briefly, paraffin sections of skin samples were deparaffinized in xylene, rehydrated in a graded series of ethanol, fixed in 4% Abbreviations DMBA 7,12-dimethylbenz(a)anthracene EGF epidermal growth factor EGFR epidermal growth factor receptor TGF-β transforming growth factor β TPA 12-O-tetradecanoylphorbol-13-acetate paraformaldehyde for 30 min and permeabilized with 20 µg/ml proteinase K for 10 min at room temperature. The slides were then incubated with terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end-labeling (TUNEL) reaction buffer in a 37°C humidified chamber for 1 h, washed twice with 2× SSC and then incubated with 4′,6-diamidino-2-phenylindole for 1 min at room temperature. Stained apoptotic cells were visualized using a LSM700 confocal microscope (Carl Zeiss, Thornwood, NY).
Immunoblotting and immunoprecipitation
Skin tissues were harvested and lyzed in a buffer consisting of 25 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (pH 7.5), 150 mM NaCl, 1% Triton X-100, 10% glycerol, 5 mM ethylenediaminetetraacetic acid, phosphatase inhibitors (Sigma) and a protease inhibitor cocktail (Roche, Indianapolis, IN). After 30 min on ice, debris were removed by centrifugation at 10 000g for 10 min. Protein concentrations were determined by the bicinchoninic acid method (Pierce, Rockford, IL) with bovine serum albumin as a standard. Next, proteins were separated by sodium dodecyl sulfate -polyacrylamide gel electrophoresis, transferred onto an Immobilon PVDF membrane (Millipore, Bedford, MA) and probed with the appropriate primary antibodies. Antibody-bound proteins were visualized with a chemiluminescence method (Pierce). Band intensity of a phosphoprotein was quantified and compared with the intensity of total protein (fold-ctl). The data were presented as means ± SD of three independent experiments. For immunoprecipitation, the skin lysates were incubated with a specific antibody overnight at 4°C, followed by treatment with protein A-Excellose beads (Bioprogen, Daejeon, Korea) for 1.5 h at 4°C. The beads were washed four times with the buffer used for cell solubilization. Next, immune complexes were eluted by boiling for 5 min in 2×
Tris-glycine SDS sample buffer and were analyzed by immunoblotting as described earlier.
Statistical analysis
Results from at least three separate experiments were expressed as mean ± SD. Student's t-test was conducted for comparisons between control and treatment groups. The significance of tumor incidence among different groups was compared by Fisher's exact test. Differences between or among samples were considered significant at P-values <0.05.
Results
SMAD7 promotes skin tumorigenesis in an in vivo mouse model
To investigate the role of SMAD7 in skin carcinogenesis, we used Smad7 transgenic mouse models expressing either FLAG-tagged wild-type Smad7 (Smad7-WT) or mutant Smad7 ( ) in the C-terminal region, which is important for inhibition of tumor necrosis factor-α signaling through the TAB2 or TAB3 interaction (2, 18) . We also generated mice with a Smad7 conditional knockout (Smad7 independent experiments performed on 10 mice per group. The data are presented as the means ± SD of three independent experiments; * P < 0.05 and ** P < 0.01.
at Carcinogenesis Online) and the skin-specific expression was confirmed (Supplementary Figure 1D, -K14Cre mice. The murine strains were treated topically with DMBA (25 µg) followed by topical application of TPA three times a week for 25 weeks ( Figure 1A) . In three independent experiments, we observed a significant tumor-promoting effect of SMAD7 in mice of different genetic backgrounds. As presented in Figure 1B , skin tumors developed earlier and the number of tumors per mouse (tumor multiplicity) was significantly greater in group TG-Smad7-WT compared with groups TG-Smad7-MT and non-TG control. This difference in tumor formation was statistically significant between groups TG-Smad7-WT and non-TG control (P < 0.01). Papillomas were first observed in TG-Smad7-WT mice after 6 weeks of TPA treatment and by week 12, 100% of these mice had developed an average of 12 tumors per mouse.
In contrast, only approximately 80% of TG-Smad7-MT or non-TG control mice formed skin tumors (~4 tumors per mouse) with longer latency (8 weeks) after TPA treatment compared to TG-Smad7-WT mice ( Figure 1C ). As expected, Smad7 2f/2f -K14Cre mice showed marked resistance to DMBA/TPA-induced skin tumor formation relative to the Smad7 2f/2f mouse strain (P < 0.05). Only 65% Smad7 2f/2f -K14Cre mice developed skin tumors, and tumor numbers were less than two per mouse, with a smaller tumor size ( Figure 1D and E) . Nonetheless, the differences in the tumor incidence were not statistically significant among different mouse groups. Representative pictures of mice with different Smad7 genotypes at the end of the experiment are given in Figure 1F . Taken together, these data indicated that SMAD7 may promote the chemical-induced skin tumorigenesis.
SMAD7 prevents DNA damage-induced cell death by enhancing ATM activity
Previous studies indicate that SMAD7 is recruited to DNA damage sites and may promote cell survival after DNA damage by enhancing ATM-dependent DNA repair signaling (19, 20) . To investigate a possible effect of SMAD7 on the DMBA-induced DNA damage response in epidermal keratinocytes, we examined To determine whether SMAD7 enhances the interaction of NBS1 with ATM in response to DMBA treatment, protein samples were prepared from cell lysates at the indicated time points after treatment with DMBA. FLAG-tagged SMAD7 in transgenic mice was pulled down with an anti-FLAG antibody, (E) or endogenous SMAD7 was pulled down with an antibody specific for SMAD7 (F). Then, western blotting was performed using specific antibodies and analysis of relative intensity of bands.
Representative gels from at least three different experiments are shown. β-Actin served as the loading control in total tissue lysate (TTL).
the activity of ATM signaling in DMBA-treated mouse skin samples. All mouse strains were topically treated with a high concentration of DMBA (100 µg per 200 µl), and then mouse skin samples were isolated at the indicated time points. As illustrated in Figure 2A and B, phosphorylation of ATM was observed after 2 h of DMBA treatment in all mouse strains, but the highest activation was detected in TG-Smad7-WT keratinocytes compared with non-TG and TG-Smad7-MT keratinocyte. Conversely, the deficiency of SMAD7 in keratinocytes markedly suppressed the phosphorylation of ATM, and the ATM signaling almost disappeared at 6 h ( Figure 2C and D) . We also observed phosphorylation of histone H2AX, which is recruited into the vicinity of DNA lesions, and the persistent presence of γH2AX foci was suggestive of delayed repair in response to DMBA. Phosphorylation of γH2AX decreased at 6 h in TG-Smad7-WT keratinocytes, but persisted in non-TG and TG-Smad7-MT groups (Figure 2A ). In contrast, Smad7 2f/2f -K14Cre mice showed greater phosphorylation of H2AX as compared with the control (Figure 2C ). These results indicated that SMAD7 can enhance DNA break repair by promoting ATM signaling. To demonstrate the specific expression of γH2AX in epidermal cells, we performed immunofluorescence analysis on tissues from transgenic or conditional knockout mice. Lower expression of γH2AX was detected in the TG-Smad7-WT epidermis than in non-TG or TG-Smad7-MT epidermis (Supplementary Figure 2A , available at Carcinogenesis Online). In contrast, the number of γH2AX-positive cells was greater in the epidermis of Smad7 2f/2f -K14Cre mice compared with the control mice (Supplementary Figure 2B , available at Carcinogenesis Online).
One study suggests that SMAD7 acts as an upstream regulator of ATM signaling upon X-ray irradiation. SMAD7 directly interacts with NBS1, thus facilitating the recruitment of ATM to the MRN complex after X-ray irradiation (19) . In the present study, we hypothesized that SMAD7 increases DMBA-induced ATM activation by facilitating the interaction of NBS1 with ATM in response to DMBA treatment. To determine the effect of SMAD7 on the interaction of NBS1 and ATM, we performed an immunoprecipitation assay. A strong interaction of NBS1 with p-ATM was detected in TG-Smad7-WT keratinocytes after 2 h of treatment with DMBA, and the interaction diminished at 6 h ( Figure 2E ). In contrast, the deficiency of SMAD7 blocked the interaction of NBS1 with p-ATM ( Figure 2F ). These data indicated that SMAD7 is critical for the NBS1-ATM interaction and for activation of ATM signaling after treatment with DMBA.
Because the activation of γH2AX and ATM signaling has been reported to correlate with cell survival after DNA damage (21), we tested whether expression of SMAD7 influences the apoptosis process by a TUNEL assay. The TUNEL staining revealed that the numbers of apoptotic cells were markedly lower in the epidermis of TG-Smad7-WT mice (relative to the control) Figure 3A, available at Carcinogenesis Online). In contrast, the number of TUNELpositive cells was higher in the epidermis of Smad7 2f/2f -K14Cre mice than that in the epidermis of control mice (Supplementary Figure 3B , available at Carcinogenesis Online). Because the survival of mutation-bearing cells is critical for tumor initiation in chemical-induced skin carcinogenesis, these data suggest that epidermal SMAD7 promotes DMBA/TPA-induced skin tumorigenesis by preventing DNA damage-induced cell death.
SMAD7 enhances TPA-induced keratinocyte proliferation
To determine whether SMAD7 sensitizes keratinocytes to TPAinduced epidermal proliferation, mice from the five groups were topically treated with TPA (10 µg) three times a week for 2 weeks. Untreated mice from all the groups had similar numbers of PCNA-positive cells ( Figure 3A) , indicating that overexpression of SMAD7 in the epidermis did not affect the basal proliferation of these cells in mice. Nonetheless, the percentage and yield of PCNA-positive cells were significantly higher in TG-Smad7-WT mice than in TG-Smad7-MT or non-TG mice 24 h after the last treatment with TPA ( Figure 3A and B) . In contrast, we observed a significant reduction in the number of PCNA-positive cells in Smad7 2f/2f -K14Cre mice compared with the Smad7 2f/2f control ( Figure 3A and C) . These data revealed that the specific expression of SMAD7 on keratinocytes may have an influence on keratinocyte proliferation at the promotion stage of the model of DMBA/TPA-induced skin carcinogenesis. In agreement with the hyperproliferation of TPA-treated keratinocytes, papillomas generated in TG-Smad7-WT mice after 25 weeks of treatment with DMBA and TPA also contained a significantly higher percentage (~3-fold) of PCNA-positive tumor cells relative to TG-Smad7-MT and non-TG control papillomas. Conversely, the number of PCNA-positive tumor cells in Smad7 2f/2f -K14Cre papillomas decreased by ~50% in comparison with Smad7 2f/2f papillomas ( Figure 3A and C) .
Analysis of epidermal lysates also indicated that the basal level of cyclin D1 was the highest in group TG-Smad7-WT and gradually increased in response to TPA (Figure 3D and E) . Conversely, cyclin D1 was downregulated in the TPA-treated Figure 4 . SMAD7 is a critical activator of EGF-mediated signaling. (A-C) To determine the effect of SMAD7 on the activation of EGFR signaling, groups of mice were treated with TPA four times and skin tissues were collected at 2 and 6 h after the last treatment with TPA. The protein lysates were isolated from skin tissues and analyzed to measure the expression levels of total EGFR as well as activation of EGFR, ERK, and STAT3 signaling in non-TG, TG-Smad7-WT, and TG-Smad7-MT mice (A) as well as in Smad7 2f/2f and Smad7 2f/2f -K14Cre mice (C). (B and D) Band intensity of a phosphoprotein was quantified and compared with that of the total protein (fold-ctl).
The data are presented as the means ± SD of three independent experiments; ** P < 0.01. To determine the effect of SMAD7 on the interaction between c-Cbl and EGFR as well as on ubiquitination and degradation of EGFR, skin tissue lysates of Smad7 knockout mice were subjected to immunoprecipitation with an antibody specific for EGFR, followed by immunoblotting with anti-c-Cbl and anti-EGFR antibodies (E) or detection with anti-phosphotyrosine, anti-ubiquitin and anti-EGFR antibodies (F). The total cell lysates were immunoblotted with r antibodies and relative intensity of bands was analyzed. (G) Activation of EGFR, ERK and STAT3 signaling was also analyzed by western blotting using specific antibodies in skin tumors with analysis of relative band intensity. N: normal mouse skin tissues, T: mouse skin tumors.
β-Actin was quantified as a control. Representative gels of at least three different experiments are shown. (H) Band intensity of a phosphoprotein was quantified and compared with that of the total protein (fold-ctl). The data are presented as the means ± SD of three independent experiments; ** p < 0.01.
Smad7
2f/2f -K14Cre epidermis compared with the Smad7 2f/2f control group ( Figure 3F and G). These findings suggested that SMAD7 enhances the formation of skin tumors through inhibition of DMBA-induced apoptosis at the initiation stage and via activation of keratinocyte proliferation at the promotion stage.
SMAD7 enhances the TPA-induced EGFR activation
One study shows activation of EGFR concomitant with elevated expression of its ligands; these changes are constitutive in skin papillomas generated by the two-stage DMBA-TPA regimen (22, 23) . In vitro overexpression of SMAD7 also induces EGF-like growth factors (TGF-α, heparin binding-EGF and amphiregulin) and tyrosine phosphorylation of EGF receptor (8) . Recently, our group found that SMAD7 promotes EGF signaling through inhibition of the ligand-induced EGFR degradation by blocking its ubiquitination process (18) . To evaluate the relation of SMAD7 with EGFR signaling during skin carcinogenesis, we checked the activation of EGFR signaling in mouse skin and tumor tissues after treatment with TPA. As presented in Figure 4A and B, the phosphorylation of EGFR increased after treatment with TPA in all the strains of mice with various Smad7 genotypes. Nonetheless, activation of EGFR signaling significantly increased and persisted at this level in TG-Smad7-WT mouse skin as compared with the other strains. Likewise, the activation of downstream kinases, such as extracellular signal-regulated kinases (ERKs) 1 and 2, was highly enhanced in TPA-treated TG-Smad7-WT mouse skin. Consistent with the previous reports on EGFR-mediated activation of STAT3 during multistage skin carcinogenesis (24) , activation of STAT3 also increased in TG-Smad7-WT mice ( Figure 4A and B). To confirm the direct effect of SMAD7 on DMBA/TPAinduced EGFR signaling, we compared the activation of EGFR signaling between mouse strains Smad7 2f/2f and Smad7 2f/2f -K14Cre after treatment with DMBA and TPA. Deficiency of epidermal SMAD7 significantly suppressed DMBA/TPA-induced EGFR activation as well as its downstream signaling (Figure 4C and D) .
Previously, we have reported that SMAD7 promotes EGFR activity by sequestering c-Cbl to suppress the ubiquitination and degradation of EGFR (18) . To further investigate the participation of SMAD7 in the regulation of the interaction between EGFR and c-Cbl as well as EGFR ubiquitination, binding assays were performed on mouse skin lysates. Deficiency of epidermal SMAD7 enhanced the formation of the c-Cbl-EGFR complex after TPA stimulation ( Figure 4E ) and was followed by increased ubiquitination and degradation of EGFR in skin tissue ( Figure 4F ). These data suggested that SMAD7 has an important function in skin tumorigenesis as a positive regulator of EGFR signaling. In addition to activation of EGFR signaling at the early stage, stronger EGFR signaling persisted even at the late stage. As shown in Figure 4G and H, the constitutive activation of EGFR was greater in TG-Smad7-WT tumors than that in non-TG control (fold-ctl) . The data are presented as the means ± SD of three independent experiments; * P < 0.05, ** P < 0.01 and *** P < 0.001.
or TG-Smad7-MT tumors. Thus, we suggest that overexpression of SMAD7 in the epidermis enhances the activation EGFR and its downstream signaling, which are important for TPA-induced epidermal proliferation and skin carcinogenesis.
Inhibition of EGF signaling blocks the SMAD7-promoted skin carcinogenesis
To determine whether SMAD7-enhanced EGFR activation is crucial for TPA-induced skin carcinogenesis, we subjected TG-Smad7-WT mice to the skin carcinogenesis protocol with or without EGFR inhibitor cetuximab (50 μg per mouse). Inhibition of EGFR signaling by cetuximab strongly reduced the tumor incidence and tumor multiplicity in TG-Smad7-WT mice ( Figure 5A ). Besides, PCNA staining indicated that treatment with cetuximab suppressed the epidermal thickening and cellular hyperproliferation in the epidermis of mouse skin ( Figure 5B ). In agreement with the results from Smad7 2f/2f -K14Cre mouse skin, we found that treatment with cetuximab significantly enhanced the degradation of EGFR in response to TPA stimulation, thereby leading to the prevention of EGFR activation and arresting its downstream signaling ( Figure 5C and D).
Discussion
SMAD7 has been reported to possess both tumor-promoting and tumor-suppressive properties (25) . Here, we demonstrated for the first time that SMAD7 enhances skin tumor formation in a model of two-stage chemical-induced carcinogenesis based on keratinocyte-specific transgenic or knockout mice. SMAD7 induced resistance to DMBA-induced apoptosis in keratinocytes and enhanced their proliferative response at the initiation stage ( Figure 6 ). Of note, both TG-Smad7-MT mice and Smad7 2f/2f -K14Cre mice, which feature a skin-specific deletion of SMAD7, were markedly resistant to DMBA/TPA-induced skin tumorigenesis. At the promotion stage, SMAD7 enhanced the cell proliferation by inducing EGFR stabilization. These results mean that the expression of SMAD7 alters a basal response of the epidermis to carcinogenic stimuli and has a crucial effect on the initiation and progression of skin tumors.
Some reports have suggested that in vitro SMAD7 overexpression accelerates tumor progression via inhibition of TGF-β signaling and upregulation of the EGF pathway in the skin (8) . In contrast, Smad7 transgenic mice, when SMAD7 is expressed at a lower level, do not manifest increased skin carcinogenesis (26) . These studies highlight different contributions of different SMAD7 amounts to skin carcinogenesis. Nonetheless, we ruled out the involvement of TGF-β signaling in this process because both TG-Smad7-WT and TG-Smad7-MT cells still showed inhibition of TGF-β signaling (data not shown). Moreover, we detected increased activation of ATM signaling in the TG-Smad7-WT group after treatment with DMBA ( Figure 2) . We report here for the first time that the DMBA-induced ATM signaling activation is involved in two-stage chemical-induced carcinogenesis and that SMAD7 blocks DMBA-induced keratinocyte apoptosis by activating ATM signaling. SMAD7 has been reported to perform an important function in the cross talk between TGF-β and ATM signaling cascades in response to DNA damage (20) . In our study, SMAD7 blocked TGF-β-induced apoptosis and enhanced ATM signaling through a direct interaction with ATM and NBS1. Because the MH2 domain (C terminus) of SMAD7 is important for interactions with binding partners such as c-Cbl (18), Cbl-b (27) and NBS1 (19) , the TG-Smad7-MT mice, which carry point mutations in the MH2 domain, may be resistant to tumor formation because SMAD7 lost the ability to interact with those partners. In line with the mouse model of TPA-induced skin carcinogenesis, EGFR stimulates proliferation, regulates differentiation and promotes cell survival in naive skin (28, 29) . In addition, EGFR family members are significantly overexpressed in many human cancers (30) . Overexpression of EGFR in ~30% of cancers is one reason for their excessive cell proliferation and tumor growth. Therefore, the upregulation of EGFR signaling may be important for the regulation of keratinocyte hyperproliferation and resistance to DMBA-induced apoptosis in TG-Smad7-WT mouse skin. To date, various EGFR inhibitors have been developed to treat a wide range of cancers, for example, monoclonal antibodies and small-molecule inhibitors (31) . Nonetheless, EGFR inhibitors often cause adverse reactions in the skin and the most common side effects of EGFR-targeting therapies are dermatological toxicities and diarrhea, which occur in at least a half of treated patients. Therefore, novel therapeutic strategies or ways to reduce EGFR inhibitor-induced adverse effects in the skin are needed.
In this study, we proved that SMAD7 is a promoter of chemical-induced skin carcinogenesis. SMAD7 regulates survival of cells that are exposed to DNA damage and serves as an upstream regulator of EGFR-mediated skin tumorigenesis by prolonging EGFR signaling. In one study, a Smad7 antisense oligonucleotide (Mongersen) was shown to downregulate SMAD7 and prevent Crohn's disease-like colitis in mice as well as increase the clinical response without systemic adverse effects in patients with Crohn's disease (32) . Therefore, blocking EGFR signaling by repression of Smad7 may be a promising therapy that abrogates EGFR-mediated tumor progression with few adverse effects.
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